Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019, with a specific reporting date of October 11, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data provided relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: GBP 17.1842 per share.
- Transaction Volume: Ranged from 3 to 69 shares per individual transaction.
- Total Shares Acquired: 335 shares across all listed individuals.
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document solely discloses routine compliance notifications for share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions disclosed were acquisitions of ordinary shares following the re-investment of dividends paid to shareholders on October 10, 2019, under the Company's Share Reward Plan. All transactions were executed on the London Stock Exchange (XLON).
Investor Verification Checklist
- Verify that the share price of GBP 17.1842 aligns with the market price on October 10, 2019.
- Confirm the dividend payment date of October 10, 2019, in the company's shareholder communications.
- Review the company's Share Reward Plan rules to ensure the re-investment mechanism was applied correctly.
- Note that this filing does not reflect any open market purchases or sales by executives, only dividend re-investments.